Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogen inactivation technology: cleansing the blood supply.

H G Klein1

  • 1Department of Medicine and Pathology, The Johns Hopkins School of Medicine, Baltimore, MD, USA. hklein@cc.nih.gov

Journal of Internal Medicine
|February 18, 2005
PubMed
Summary

Blood transfusion safety is high for HIV, HBV, and HCV, but bacterial and emerging pathogen risks persist. New pathogen inactivation technologies show promise for improving blood component safety beyond traditional screening methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathogen-reduction methods: advantages and limits.

ISBT science series·2020
Same author

Risks of restrictive red blood cell transfusion strategies in patients with cardiovascular disease (CVD): a meta-analysis.

Transfusion medicine (Oxford, England)·2018
Same author

International Forum regarding practices related to donor haemoglobin and iron.

Vox sanguinis·2016
Same author

Transfusion of recently donated (fresh) red blood cells (RBCs) does not improve survival in comparison with current practice, while safety of the oldest stored units is yet to be established: a meta-analysis.

Vox sanguinis·2016
Same author

Preparation of granulocyte concentrates by apheresis: collection modalities in the USA.

Vox sanguinis·2011
Same author

The relevance of practice misalignments to trials in transfusion medicine.

Vox sanguinis·2010

Area of Science:

  • Transfusion Medicine
  • Infectious Disease Prevention
  • Biotechnology

Background:

  • Residual infectious risks from HIV, HBV, and HCV in blood transfusions are minimal.
  • Bacterial contamination and emerging infectious agents (viruses, protozoa, tick-borne) pose ongoing threats to blood supply safety and public confidence.
  • Traditional donor screening and testing methods have limitations in preventing transmission of novel or unknown pathogens.

Purpose of the Study:

  • To review the current state of blood safety regarding infectious agents.
  • To evaluate the efficacy and safety of existing and emerging pathogen reduction technologies for blood components.
  • To identify advancements in mitigating transfusion-transmitted infections.

Main Methods:

  • Review of current literature on blood transfusion safety and pathogen inactivation.

Related Experiment Videos

  • Analysis of traditional screening and testing limitations.
  • Assessment of pathogen inactivation technologies for plasma-derived products and blood components.
  • Evaluation of mechanical removal techniques and nucleic acid targeting methods.

    • Main Results:

    • Pathogen inactivation technologies have successfully addressed risks in plasma-derived products.
    • No single pathogen inactivation technology is yet proven safe and effective for all traditional blood components.
    • "Half-way" technologies offer risk reduction for fresh frozen plasma and cryoprecipitate.
    • Nucleic acid targeting methods are entering clinical trials with promising results.

    Conclusions:

    • While viral risks are low, bacterial and emerging pathogen threats necessitate advanced safety measures.
    • Pathogen inactivation technologies, particularly those targeting nucleic acid, represent the future of enhancing blood component safety.
    • Continued research and clinical testing are crucial for implementing safe and effective pathogen reduction strategies for all blood products.